Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Fully Diluted

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Feb 24, 2021 10:12am

169 Views

Post# 32646040

RE:RE:RE:Fully Diluted

Forestview wrote: I'm with you Mugs, but I'm using 70M. Better to be (more) conservative.

So, money hits our account today. Should be a good day. Fingers crossed. Let's end Feb with a bang.

Ya - I'll be using 70M before you know it.

I've been using 60,000,000 for over a year now.

: )

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December